KOSDAQ-listed Korean maker of lower-limb rehabilitation exoskeletons (EA2 PRO, BAM-T) that now owns Luxembourg's ExoAtlet Global.
"Cosmo Robotics Co., Ltd. is a South Korean wearable-robot manufacturer headquartered in Ace Tech Tower 5, 20 Digital-ro 31-gil, Guro-gu, Seoul, where it also manufactures. It was incorporated on 4 October 2016 as ExoAtlet Asia, the Korean arm of the ExoAtlet exoskeleton group, was absorbed into the Cosmo Group in December 2023 and renamed, and is listed on KOSDAQ under code 439960. It runs a co-chief-executive structure under Oh Joo-young and Kang Gon, and employed 56 people as of July 2026. Cosmo and Company is the largest shareholder at roughly 21 per cent, with chief executive Oh Joo-young holding about 12 per cent; no single holder controls the company outright.
The product line covers three uses of the same lower-limb exoskeleton technology. Medical rehabilitation is the core: EA2 PRO for adults, BAM-T for adolescents and BAM-K for children, used for gait rehabilitation and walking training in stroke, hemiplegia and spinal-cord patients. EA Personal extends the adult device to home use. COSuit is a walking-assistance device rather than a clinical rehabilitation one, and COSaver, including the COSaver Back variant, is an unpowered or lightly powered industrial wearable suit aimed at reducing load on workers in labour-intensive tasks. Legacy ExoAtlet and ExoAtlet II units, plus the Bambini and Bambini Mini paediatric devices, remain in the catalogue. The company reports 31 registered patents and six national research and development projects, and holds regulatory clearances in all four major markets: United States FDA, European CE, Korean MFDS and Chinese NMPA, formerly CFDA. Its adult device carries Class 3 medical-device status in Korea with National Health Insurance reimbursement approval, which matters because reimbursement is what makes clinical purchase viable.
Revenue was KRW 5.7 billion in 2022, KRW 6.23 billion in 2023 and about KRW 7.02 billion in 2024. EA2 PRO and the BAM-T paediatric line together account for more than ninety per cent of sales. The business carries concentration risk that a directory user should weigh: the two largest customers represent roughly 64 per cent of revenue, accounts receivable rose from KRW 220 million at the end of 2022 to KRW 5.98 billion by the third quarter of 2025, and Korean analysts have flagged dependence on Russian state rehabilitation procurement as a structural exposure inherited from the ExoAtlet origin. The company was also loss-making at the operating line in 2024 and guided to tripling sales within three years of listing.
In May 2026 Cosmo Robotics became the holding company of ExoAtlet Global S.A. of Luxembourg, the European entity of the original ExoAtlet group. The two continue to present separately, with the ExoAtlet brand and its own website still operating, but ownership now sits in Seoul. Cosmo Robotics maintains offices in Seoul, Shanghai, Tokyo, the United States and Luxembourg.
The company therefore occupies an unusual position: a Korean-listed manufacturer that both descends from and now owns a European exoskeleton brand, selling clinical rehabilitation devices with reimbursement status as its revenue base while attempting to extend the same actuator and joint technology into consumer assistance and industrial wearables."
Primary type & automation activities this supplier delivers:
Company Facts
Founded
2016
Primary Role
Manufacturer
Company Size
employees 50-100
Primary Region
Asia-Pacific
Annual Sales
-
Funding Stage
-
Funding Total
-
Keywords
